Burns
Volume 34, Issue 8 , Pages 1098-1102 , December 2008

Association between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in an intensive care burn unit: A 5-year study, 2000–2004

  • Amen Allah Messadi

      Affiliations

    • Intensive Care Burn Department, Aziza Othmana Hospital, Tunis, Tunisia
  • ,
  • Thabet Lamia

      Affiliations

    • Laboratory for Resistance to Antibiotics, Faculty of Medicine, Tunis, Tunisia
    • Corresponding Author InformationCorresponding author. Tel.: +216 22975018; fax: +216 71389652.
  • ,
  • Bousselmi Kamel

      Affiliations

    • Intensive Care Burn Department, Aziza Othmana Hospital, Tunis, Tunisia
  • ,
  • Oueslati Salima

      Affiliations

    • Intensive Care Burn Department, Aziza Othmana Hospital, Tunis, Tunisia
  • ,
  • Memmi Monia

      Affiliations

    • Intensive Care Burn Department, Aziza Othmana Hospital, Tunis, Tunisia
  • ,
  • Ben Redjeb Saida

      Affiliations

    • Laboratory for Resistance to Antibiotics, Faculty of Medicine, Tunis, Tunisia

,Accepted 6 March 2008.

References 

  1. Hsueh P, Chen , Luh K. Relationships between antimicrobial use and antimicrobial resistance in Gram negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan. Int J Antimicrob Agents. 2005;26:463–472
  2. Estahbanati HK, Kashani PP, Ghanaatpisheh F. Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics. Burns. 2002;28:340–348
  3. Altopark U, Erol S, Akcay M, Celebi F, Kadanali A. The time related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns. 2004;30:660–664
  4. Mohr A, Jones A, Zeichner L, Wanger A, Tilloston G. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private university affiliated teaching hospital: an 8 year experience: 1995–2002. Int J Antimicrob Agents. 2004;346–351
  5. American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864
  6. Soussy CJ. Comité de l’antibiogramme de la SFM. Bull Soc Fr Microbiol 2001.
  7. www.who.int/drugresistance/whonet.
  8. Mise en place d’un réseau de surveillance de la consommation des antibiotiques parallèlement à certaines résistances bactériennes dans les établissements de soins de l’inter région Paris Nord. Protocole ATB 2005, CCLIN Paris Nord. www.ccr.jussien.fr/cclin.
  9. Rogues AM, Dumartin C, Parneix P, Prudhan H, Placet Th, Beneteau C, et al. Policies for the use of antibiotics in 99 Southwestern French hospitals in 2002. Med Mal Infect. 2005;
  10. Carmeli Y, Trouillet N, Eliopoulos G, Samore M. Emergence of antibiotic resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. AACN Clin Issues. 1999;43:1379–1382
  11. Lozzano J, Monnet D, Yague A, Campillos P, Gonzalo N, Burgos A. Surveillance de la résistance bactérienne et modélisation de sa relation avec les consommations d’antibiotiques au moyen de l’analyse des séries chronologiques. Bull Soc Fr Microbiol. 2002;17
  12. El Seviens M. Outpatient antibiotic use in Europe and association with resistance: a cross national database study. Lancet. 2005;365:579–587
  13. Nseir S, Dipompeo C, Soubrier S, Delour P, Lenci H, Roussel D, et al. First generation fluoroquinolone use and subsequent emergence of multiple drugs resistant in the intensive care unit. Crit Care Med. 2005;33:283–289
  14. Lepper P, Gruser E, Reich H, Hogel J, Trautmann M. Consumption of imipenem correlates with β-lactam resistance in Ps. aeruginosa. AACN Clin Issues. 2002;46:2920–2925
  15. Lopez M, Dominique L, Yague A, Gonzelo N, Campillos PS, Saez M. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis. Int J Antimicrob Agents. 2000;14:21–31
  16. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Quinn K. Antibiotic resistance among Gram negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885–888
  17. Polk R, Johnson C, Edmond M, Wenzel R. Trends in fluoroquinolone (FQ) prescribing in 35 US hospitals and resistance for Ps. aeruginosa: a scope MMIT report. Proceedings of the interscience conference on antimicrobial agents and chemotherapy. Chicago, IL: Chicago American Society for Microbiology; 2001 [Abstract UL-1].
  18. Macdougall C, Harpe S, Powell J, Johnson C, Edmont M, Polk R. Pseudomonas aeruginosa, Staphylococcus aureus and fluoroquinolone use. Emerg Infect Dis. 2005;11
  19. Harbarth S, Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram negative bacilli. CID. 2001;33:1462–1468
  20. Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C. Pseudomonas aeruginosa ventilator associated pneumonia: comparison of episodes due to piperacillin resistant versus piperacillin susceptible organisms. CID. 2002;34:1047–1054
  21. Monnet DL, Archibald LK, Phillips L, Tenover FC, Mcgowan J, Gaynes R. Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modelling. Intensive Care Antimicrobial Resistance Epidemiology Project, and National Nosocomial Infections Surveillance System Hospitals. Infect Control Hosp Epidemiol. 1998;19:388–394
  22. Paramythiotou E, Lucet J, Timsit J, Vanjak D, Butz C, Andremont A. Acquisition of multidrug resistant Ps. aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. CID. 2004;38:670–674
  23. Seir N, Ader F, Marquette CH, Durocher A. Impact de l’utilisation des fluoroquinolones sur l’émergence des bactéries multirésistants. Pathol Biol (Paris). 2005;53:470–475

PII: S0305-4179(08)00095-8

doi: 10.1016/j.burns.2008.03.014

Burns
Volume 34, Issue 8 , Pages 1098-1102 , December 2008